Document is current
Any future updates will be listed below
-
Authors
Porto, Luana L. T. N.
Yazji, Dina
Unninayar, Dana
Decaluwe, Hélène
Derfalvi, Beata
Palma, Alejandro
Issekutz, Thomas
Kalashnikova, Tatiana
Murguía-Favela, Luis
Pham-Huy, Anne
Rubin, Tamar
Suresh, Sneha
Upton, Julia
Wright, Nicola A. M.
Chapdelaine, Hugo
Falcone, Emilia Liana
Top, Karina A.
Sadarangani, Manish
Vinh, Donald C.
Barrett, Lisa
Oldford, Sharon
Langlois, Marc-Andre
Arnold, Corey
Zhang, Tinghua
Ramsay, Tim
Cowan, Juthaporn
,
Ritchie, Bruce
Buchan, Arianne C.
Kalincinsky, Chrystyna
Haddad, Elie
Touzot, Fabien
Lacuesta, Gina
Hildebrand, Kyla
Kim, Vy
Betschel, Stephen D.
-
Funding
Funding for this research was provided by:
The Canada COVID-19 Immunity Task Force, Public Health Agency of Canada (2122-HQ-000073)
- License Information
-
More Information
Article History
Received: 29 July 2025
Accepted: 11 April 2026
First Online: 25 April 2026
Declarations
:
: KAT and HD received grants from the Coalition for Epidemic Preparedness Innovations outside the submitted work. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Moderna, Pfizer and Sanofi-Pasteur. All funds have been paid to his institute, and he has not received any personal payments. JC has received consultation, speaker fees, and educational funding not related to this study from Takeda, CSL Behring, Grifols, and Octapharma, GSK, Pfizer, Astrazeneca, EMD Serono, and Avir Pharma. LMF is a member of the Data Safety Monitoring Committee for Encoded Therapeutics and has participated as an Advisory Board Member for Takeda, both unrelated to the submitted work. BD is a member of a Data Safety Monitoring Committee and has participated as an Advisory Board Member for Takeda, not related to this study. APH has received educational funding not related to this study from CSL Behring. The authors whose names are listed immediately below certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript: LLTNP, DY, DU, ELF, HC, DV, TI, JU, BS, TR, SS, NW, TK, LB, SO, MAL, CA, TZ, TR.
